Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors

E. Javorkova, N. Matejckova, A. Zajicova, B. Hermankova, M. Hajkova, P. Bohacova, J. Kossl, M. Krulova, V. Holan,

. 2019 ; 14 (2) : 215-225. [pub] 20180921

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK ProQuest Central from 2006-03-01 to 1 year ago
Medline Complete (EBSCOhost) from 2010-03-01 to 1 year ago
Health & Medicine (ProQuest) from 2006-03-01 to 1 year ago

Pathogenesis of amyotrophic lateral sclerosis (ALS) involves several mechanisms resulting in a shift from a neuroprotective to a neurotoxic immune reaction. A promising tool for ALS treatment is represented by mesenchymal stem cells (MSCs), which possess both regenerative potential and immunomodulatory properties. In this study, we aimed to compare the immunomodulatory properties of MSCs isolated from the bone marrow of patients suffering from ALS and healthy donors. Moreover, the influence of proinflammatory cytokines on the immunoregulatory functions of MSCs was also evaluated. We found that MSCs from ALS patients and healthy donors comparably affected mitogen-stimulated peripheral blood mononuclear cells and reduced the percentage of T helper (Th)1, Th17 and CD8+CD25+ lymphocytes. These MSCs also equally increased the percentage of Th2 and CD4+FOXP3+ T lymphocytes. On the other hand, MSCs from ALS patients decreased more strongly the production of tumour necrosis factor-α than MSCs from healthy donors, but this difference was abrogated in the case of MSCs stimulated with cytokines. Significant differences between cytokine-treated MSCs from ALS patients and healthy donors were detected in the effects on the percentage of CD8+CD25+ and CD4+FOXP3+ T lymphocytes. In general, treatment of MSCs with cytokines results in a potentiation of their effects, but in the case of MSCs from ALS patients, it causes stagnation or even restriction of some of their immunomodulatory properties. We conclude that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines. Graphical Abstract Treatment of mesenchymal stem cells (MSCs) with cytokines results in a potentiation of their effects, but in the case of MSCs from amyotrophic lateral sclerosis (ALS) patients, it causes stagnation (an equal reduction of the percentage of CD8+CD25+ T lymphocytes) or even restriction (no increase of proportion of CD4+FOXP3+ T lymphocytes) of some of their immunomodulatory properties. It means that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025838
003      
CZ-PrNML
005      
20201222155501.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11481-018-9812-7 $2 doi
035    __
$a (PubMed)30242613
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Javorkova, Eliska $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. eliska.javorkova@iem.cas.cz. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic. eliska.javorkova@iem.cas.cz.
245    10
$a Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors / $c E. Javorkova, N. Matejckova, A. Zajicova, B. Hermankova, M. Hajkova, P. Bohacova, J. Kossl, M. Krulova, V. Holan,
520    9_
$a Pathogenesis of amyotrophic lateral sclerosis (ALS) involves several mechanisms resulting in a shift from a neuroprotective to a neurotoxic immune reaction. A promising tool for ALS treatment is represented by mesenchymal stem cells (MSCs), which possess both regenerative potential and immunomodulatory properties. In this study, we aimed to compare the immunomodulatory properties of MSCs isolated from the bone marrow of patients suffering from ALS and healthy donors. Moreover, the influence of proinflammatory cytokines on the immunoregulatory functions of MSCs was also evaluated. We found that MSCs from ALS patients and healthy donors comparably affected mitogen-stimulated peripheral blood mononuclear cells and reduced the percentage of T helper (Th)1, Th17 and CD8+CD25+ lymphocytes. These MSCs also equally increased the percentage of Th2 and CD4+FOXP3+ T lymphocytes. On the other hand, MSCs from ALS patients decreased more strongly the production of tumour necrosis factor-α than MSCs from healthy donors, but this difference was abrogated in the case of MSCs stimulated with cytokines. Significant differences between cytokine-treated MSCs from ALS patients and healthy donors were detected in the effects on the percentage of CD8+CD25+ and CD4+FOXP3+ T lymphocytes. In general, treatment of MSCs with cytokines results in a potentiation of their effects, but in the case of MSCs from ALS patients, it causes stagnation or even restriction of some of their immunomodulatory properties. We conclude that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines. Graphical Abstract Treatment of mesenchymal stem cells (MSCs) with cytokines results in a potentiation of their effects, but in the case of MSCs from amyotrophic lateral sclerosis (ALS) patients, it causes stagnation (an equal reduction of the percentage of CD8+CD25+ T lymphocytes) or even restriction (no increase of proportion of CD4+FOXP3+ T lymphocytes) of some of their immunomodulatory properties. It means that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines.
650    _2
$a amyotrofická laterální skleróza $x imunologie $7 D000690
650    _2
$a buňky kostní dřeně $x imunologie $7 D001854
650    _2
$a cytokiny $x metabolismus $7 D016207
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x farmakologie $7 D007155
650    _2
$a imunomodulace $7 D056747
650    _2
$a leukocyty mononukleární $x účinky léků $x imunologie $7 D007963
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mezenchymální kmenové buňky $x imunologie $7 D059630
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mitogeny $x farmakologie $7 D008934
650    _2
$a T-lymfocyty pomocné-indukující $x účinky léků $x imunologie $7 D006377
650    _2
$a TNF-alfa $x biosyntéza $7 D014409
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Matejckova, Nicole $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
700    1_
$a Zajicova, Alena $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic.
700    1_
$a Hermankova, Barbora $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
700    1_
$a Hajkova, Michaela $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
700    1_
$a Bohacova, Pavla $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
700    1_
$a Kossl, Jan $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
700    1_
$a Krulova, Magdalena $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
700    1_
$a Holan, Vladimir $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
773    0_
$w MED00201263 $t Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology $x 1557-1904 $g Roč. 14, č. 2 (2019), s. 215-225
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30242613 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155457 $b ABA008
999    __
$a ok $b bmc $g 1599983 $s 1116524
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c 2 $d 215-225 $e 20180921 $i 1557-1904 $m Journal of neuroimmune pharmacology $n J Neuroimmune Pharmacol $x MED00201263
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...